Sun Pharma has launched the Favipiravir tablet in India at an economical rate ₹35 per pill to treat mild to moderate COVID-19 patients.
On August 4, 2020, Sun Pharmaceutical Industries Ltd had launched the FluGuard® (Favipiravir 200 mg) tablet for ₹35 per pill in India. In India, it is the only oral anti-viral treatment approved for the potential treatment of patients with mild to moderate COVID-19 disease.
Kirti Ganorkar, CEO of India Business at Sun Pharma, said that with increasing numbers of positive cases daily in India, there was an urgent need to provide more treatment options to healthcare professionals. By launching the pills at an economical price, it can reach more and more patients without any financial burden. The company will work closely with the government and medical community to ensure it reaches all the country's patients.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.